Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2019

View Archived Issues

Neurotransmitter receptor stimulates early blood cell progenitors

Presentation of phase I results of PEN-866 in patients with advanced solid tumors

Knockdown of Fas death receptor shows hepatoprotective effect against NASH in mice

Novel PDE-delta inhibitor disrupts its interaction with mutant KRAS and inhibits tumor growth

BETonMACE phase III epigenetics study does not meet primary endpoint

Cabaletta Bio receives FDA IND clearance to initiate first-in-human study of DSG3-CAART

FDA clears IND for rapid personalized manufacture of CD19-specific CAR-T

TLC initiates phase III pivotal EXCELLENCE study of TLC-599

Preclinical and early clinical data for BBT-877 reported

Fluzoparib shows promising antitumor activity in advanced BRCA1/2-mutated ovarian cancer

Phase II data presented for ampreloxetine as treatment of neurogenic orthostatic hypotension

RELIEF study supports use of pirfenidone in non-IPF lung fibrosis

PharmaBlock Sciences patents PRMT5 inhibitors

Fujian Haixi Pharmaceuticals presents new CSF-1R inhibitors

Sunshine Lake Pharma identifies new PD-1/PD-L1 interaction inhibitors

Agenus patents anti-CD73 antibodies for cancer

Lundbeck discloses antibodies targeting tau

Phase II study of NCX-470 in open-angle glaucoma or ocular hypertension meets primary endpoint

Equillium initiates phase Ib study of itolizumab in lupus nephritis

Humanetics' development of radioprotectant BIO-301 supported by DoD cooperative research agreement

Checkmate's CMP-001 studied in combinations with Bavencio for SCCHN

IL-11 identified as therapeutic target in pulmonary fibrosis

New registrational study evaluates miransertib in Proteus syndrome and PROS

ContraFect plans single phase III study of exebacase for S. aureus bacteremia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026